Technology | October 17, 2011

FDA Clears LeGoo for Surgical Blood Flow Control


October 17, 2011 — The U.S. Food and Drug Administration (FDA) has approved LeGoo, a gel allowing surgeons to temporarily stop blood flow during surgery. This makes it possible to join blood vessels without clamps or elastic loops.

To join blood vessels during surgery, it is necessary to temporarily stop blood flow to the area where a new vessel is being attached. Stopping blood flow prevents flooding of the surgical area, which makes it difficult for the surgeon to clearly see where to place sutures.

LeGoo has been shown to minimize blood flow into the surgical area without damaging blood vessels. Standard tools, such as elastic loops and clamps, do not always allow for a bloodless surgical area and may damage vessels.

“LeGoo is an innovative device that offers surgeons an additional aid during vascular surgery,” said Christy Foreman, director of the Office of Device Evaluation in the FDA’s Center for Devices and Radiological Health. “The gel’s unique properties may facilitate surgeries that entail the joining or grafting blood vessels.”

The temperature-sensitive gel is liquid at room temperature and solid beyond that. When injected into a blood vessel, it forms a gel plug that molds to the shape of the blood vessel and stops blood flow for up to 15 minutes.

After the blood vessels are joined, the plug should dissolve on its own in 15 minutes. In the event it needs to dissolve sooner, the surgeon can apply a cold pack or cold saline to the blood vessel.

In support of approval of the pre-marketing application, the FDA reviewed studies showing LeGoo is biocompatible and non-toxic. The agency also looked at data from a clinical trial of 110 patients undergoing bypass surgery without stopping the heart (off pump coronary artery bypass).

Investigators found the gel is as safe and effective as vessel loops, devices commonly used to stop blood flow during coronary bypass surgery.

It is approved for temporarily stopping blood flow in blood vessels below the neck that are 4 millimeters or less in diameter. It is contraindicated for use on vessels supplying blood to the brain.

LeGoo is manufactured by PluroMed Inc. of Woburn, Mass.

For more information: www.fda.gov/medicaldevices


Related Content

News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
News | Cardiovascular Surgery

December 18, 2023 — The Department of Cardiovascular Surgery at The Mount Sinai Hospital has received the highest ...

Home December 18, 2023
Home
News | Cardiovascular Surgery

November 2, 2023 — The University of Maryland Medical Center (UMMC) released a statement on the passing of a patient ...

Home November 02, 2023
Home
News | Cardiovascular Surgery

October 25, 2023 — Edwards Lifesciences announced new data from the PARTNER 3 trial demonstrating continued low rates of ...

Home October 25, 2023
Home
Subscribe Now